Latest Cholesterol News

corner spacer corner spacer corner spacer corner spacer

4 October, 2007 - Merck's Investigational CETP-Inhibitor, MK-0859 - anacetrapib
Merck & Co. announced today that Phase IIb study results showed that anacetrapib significantly reduced LDL-cholesterol (LDL-C) and increased HDL-cholesterol (HDL-C) both alone and in combination with atorvastatin 20 mg compared to placebo in patients with primary hypercholesterolemia or mixed hyperlipidemia. Several dosages were tested during the eight week study, including 10, 40, 150 and 300 mg. LDL-C levels were reduced 16%, 27%, 40% and 39% and HDL-C levels were increased 44%, 86%, 139% and 133% respectively. Dosages were also tested in combination with atorvastatin and produced significant incremental reductions in LDL-C and increases in HDL-C when compared to atorvastatin alone. All told, there were 10 separate studied groups, including 4 various dosages with anacetrapib alone, 4 with a combination of various dosages with anacetrapib with 20mg atorvastatin and two placebo. Another bright spot - there was no significant indication of raised blood pressure during the test. is not dispensing medical advice. Questions about your own cholesterol levels should be addressed to your physician.

The Prescription Free Cholesterol Cure Drop your high cholesterol in an all-natural way using the Mangano method.


Private Cholesterol Tests

Lower Your Cholesterol Sitemap

Instant Cholesterol Test by Home Access
Instant Cholesterol Test by Home Access

Third Report of the National Cholesterol Education Program

Other Links


corner spacer corner spacer corner spacer corner spacer

Shop For Vitamins & Supplements At eVitamins